Moderna, Inc. (NASDAQ:MRNA) Stake Lessened by Pinebridge Investments L.P.

Pinebridge Investments L.P. cut its stake in Moderna, Inc. (NASDAQ:MRNA) by 59.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,646 shares of the company’s stock after selling 22,700 shares during the period. Pinebridge Investments L.P.’s holdings in Moderna were worth $651,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Inspire Trust Co. N.A. boosted its holdings in Moderna by 73.5% during the third quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company’s stock worth $1,104,000 after buying an additional 7,000 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Moderna by 4.2% during the third quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock worth $25,359,000 after buying an additional 15,218 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Moderna by 31.9% in the 4th quarter. GAMMA Investing LLC now owns 3,173 shares of the company’s stock valued at $132,000 after acquiring an additional 768 shares in the last quarter. Douglas Lane & Associates LLC lifted its position in shares of Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after acquiring an additional 298,715 shares in the last quarter. Finally, Czech National Bank lifted its position in shares of Moderna by 6.6% in the 4th quarter. Czech National Bank now owns 73,424 shares of the company’s stock valued at $3,053,000 after acquiring an additional 4,526 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the subject of several research analyst reports. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. UBS Group reduced their price target on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. William Blair restated a “market perform” rating on shares of Moderna in a research report on Thursday, April 17th. Citigroup assumed coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price target for the company. Finally, Leerink Partners cut their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $58.70.

Moderna Trading Up 0.9 %

NASDAQ:MRNA opened at $27.46 on Tuesday. The firm has a market capitalization of $10.62 billion, a PE ratio of -2.96 and a beta of 2.23. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The firm’s fifty day simple moving average is $30.03 and its 200 day simple moving average is $38.15.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.